Is Extended-Release Guaifenesin No Better Than a Placebo?

@article{OConnell2014IsEG,
  title={Is Extended-Release Guaifenesin No Better Than a Placebo?},
  author={Oisin J. O’Connell},
  journal={Respiratory Care},
  year={2014},
  volume={59},
  pages={788 - 789}
}
In this issue of Respiratory Care, Hoffer-Schaefer et al[1][1] report the results of a double-blind randomized placebo-controlled trial examining the effects of guaifenesin on both the volume and physical properties of sputum in patients with acute respiratory tract infections (RTIs). Guaifenesin 

References

SHOWING 1-10 OF 11 REFERENCES

Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

Results from the clinical pilot and validation studies showed that the SUM8 diary scores were robust and reliable for use as efficacy endpoints in studies of mucoactive drugs.

Guaifenesin Has No Effect on Sputum Volume or Sputum Properties in Adolescents and Adults With Acute Respiratory Tract Infections

The recommended dose of GGE had no measurable effect on sputum volume or properties and is unlikely to be an expectorant or mucolytic when used to treat acute RTI.

Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings.

There is no good evidence for or against the effectiveness of OTC medicines in acute cough, and higher quality evidence is needed to determine the effective of self care treatments for acute cough.

Over-the-counter (OTC) medications for acute cough in children and adults in community settings.

There is no good evidence for or against the effectiveness of OTC medicines in acute cough, with higher numbers of adverse effects in participants taking preparations containing antihistamines and dextromethorphan.

Mucoactive agents for airway mucus hypersecretory diseases.

  • D. Rogers
  • Biology, Medicine
    Respiratory care
  • 2007
With the exception of mucoregulatory agents, whose primary action is unlikely to be directed against mucus, well-designed clinical trials are required to unequivocally determine the effectiveness of expectorant, mucolytic, and mucokinetic agents in airway diseases in which mucus hypersecretion is a pathophysiological and clinical issue.

Nebulized Hypertonic Saline Via Positive Expiratory Pressure Versus Via Jet Nebulizer in Patients With Severe Cystic Fibrosis

Hypertonic saline via PEP nebulizer benefits CF patients who do not tolerate hypertoni saline via jet nebulized patients with severe CF pulmonary disease.

Therapeutic aerosols and airway secretions.

  • B. Rubin
  • Medicine, Biology
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine
  • 1996
The in vitro effects of synthetic surfactant on the physical and transport properties of sputum from 15 patients with CF and 30 patients with stable chronic bronchitis were assessed, raising the possibility of using surfactants as a mucokinetic agent in the therapy of chronic suppurative lung disease.

Unpacking a gel-forming mucin: a view of MUC5B organization after granular release.

Using OptiPrep density gradient ultracentrifugation, a small amount of a stable form of the recently secreted and expanding MUC5B mucin is isolated, providing some insight into how the carbohydrate regions might be organized around the NH(2)- and COOH-terminal globular protein domains within the granule and also explains how the mucin can expand so rapidly upon its release.

Mucins, mucus, and sputum.

Mucin glycoprotein overproduction and hypersecretion are common features of chronic inflammatory airway disease, and this has been the underlying rationale to investigate the mechanisms of mucin gene regulation and mucin secretion.

Guidance for FDA staff and industry: marketed unapproved drugs-compliance policy guide